Objective: To establish a quantitative analysis method for pharmacokinetics and bioavailability of breviscapine phospholipid complex self-microemulsions in Beagle dogs. Method: Beagle dogs were administered with breviscapine phospholipid complex self-microemulsions and breviscapine tablets at single dose

respectively.HPLC was adopted to determine the concentration of scutellarin in plasma with mobile phase of methanol-0.2% phosphoric acid solution(45:55) and detection wavelength at 335 nm.Pharmacokinetics parameters and bioavailability was calculated by DAS2.1.1 software program. Result: Plasma concentration-time profiles of scutellarin in these two preparations were fitted to double-compartment model

Tmaxof breviscapine phospholipid complex self-microemulsions and breviscapine tablets were 190 min and 160 min

Cmax were 78.98 mg·L-1 and 33.63 mg·L-1

AUC0-twere 18 674.619 mg·L-1·min and 9 132.475 mg·L-1·min

respectively.Relative bioavailability of self-microemulsions relative to tablets was 204.49%. Conclusion: Breviscapine phospholipid complex self-microemulsions can significantly improve bioavailability of scutellarin in Beagle dogs

which provides a new direction for development of oral preparations of breviscapine.